Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of oral CF101 in moderate-to-severe plaque psoriasis
2008-005904-13Phase 2Completed
- Sponsor
- Can-Fite BioPharma Ltd.
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of piclidenoson in plaque psoriasis (4 arms), sponsored by Can-Fite BioPharma Ltd. Primary endpoints: Change from baseline in PASI score, Percent change from baseline in PASI score and 2 more. Started Jan 2009; status: completed.
02
Drugs
piclidenoson
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2008-005904-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005904-13.